MirZyme Therapeutics

MirZyme Therapeutics develops diagnostic and therapeutic approaches aimed at preventing preeclampsia and fetal growth restriction.

Its laboratory test assesses pregnancy risk using biomarkers combined with a clinical decision-support tool. The company is also developing oral treatments based on patented enzyme technology.

The programmes are intended to identify complications earlier and support treatment decisions for patients at risk, connecting maternal health diagnostics with drug development.